Name: Artemisinin
Brand: Selleck Chemicals
SKU: S1282
Availability: InStock
Rating: 5 (10 reviews)

Jump to

Quality Control

Batch: Purity: 99.83%

99.83

Related Targets	Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV
Other ADC Cytotoxin Inhibitors	Triptolide SN-38 Luteolin (+)-Bicuculline Rutin BHQ Pinocembrin Luteoloside Psoralen Lappaconite HBr

Solubility

In vitro
Batch:

DMSO : 57 mg/mL (201.89 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 24 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	3%DMSO 1 97%Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	6.000mg/ml (21.25mM)	Taking the 1 mL working solution as an example, add 30 μL of 200 mg/ml clear DMSO stock solution to 970 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	282.33	Formula	C₁₅H₂₂O₅	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	63968-64-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Qinghaosu, NSC 369397			SMILES	CC1CCC2C(C(=O)OC3C24C1CCC(O3)(OO4)C)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro

Artemisinin's antimalarial activity has been shown to be mediated by activated oxygen (i.e., superoxide, hydrogen peroxide, and/or hydroxyl radicals). This compound and heroin appear to be forming an adduct whose behavior resembles the behavior of the parasite this compound product. Its activity can be potentiated by oxygen and oxidizing agents and attenuated by reducing agents. This compound susceptibility can be influenced by genetic changes in the loci encoding P. falciparum multidrug resistance protein 1 (PfMDR1) and P. falciparum CHQ resistance transporter (PfCRT). It is effective not only against multi-resistant strains of P. falciparum, but have broad stage specificity against the Plasmodium life cycle including activity throughout the asexual blood stages and also the sexual gametocyte stages which may reduce the spread of the disease in areas of low transmission. This chemical has also been investigated for its antiproliferative effects against a wide range of cancer cell lines. It is active against other parasite species such as Toxoplasma and Babesia that do not contain hematin. This compound results in decreased proliferation, increased levels of oxidative stress, induction of apoptosis and inhibition of angiogenesis in cancer cells. It has also been shown to inhibit the falcipains, a papain family cysteine protease that aid hemoglobin degradation.

References

[1] https://pubmed.ncbi.nlm.nih.gov/1775162/
[2] https://pubmed.ncbi.nlm.nih.gov/19881520/
[3] https://pubmed.ncbi.nlm.nih.gov/20336009/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-04-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07533136	NOT_YET_RECRUITING	Uncomplicated P. Vivax Mono-infection	Walter Reed Army Institute of Research (WRAIR)	2026-05-01
NCT06962319	RECRUITING	Malaria, Pregnancy; Malaria, Antepartum; Malaria (Uncomplicated)	Liverpool School of Tropical Medicine	2025-09-30	PHASE3
NCT04704999	RECRUITING	Plasmodium Vivax Malaria	University of Oxford	2024-07-22	PHASE4
NCT07403643	NOT_YET_RECRUITING	Uncomplicated Malaria	Curtin University	2026-04	PHASE4
NCT05951595	RECRUITING	Uncomplicated Plasmodium Falciparum Malaria	University of Oxford	2025-09-11	PHASE3
NCT05788094	RECRUITING	Malaria; Malaria, Vivax; Plasmodium Vivax Malaria	Shoklo Malaria Research Unit	2023-06-26	PHASE4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Artemisinin ADC Cytotoxin inhibitor

Chemical Structure

Molecular Weight: 282.33